Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

First published online July 5, 2007
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
2007-0164v1
25/11/2837    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karnieli, O.
Right arrow Articles by Efrat, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karnieli, O.
Right arrow Articles by Efrat, S.
Submitted on March 7, 2007
Accepted on June 26, 2007

TISSUE-SPECIFIC STEM CELLS

Generation of Insulin-producing Cells From Human Bone Marrow Mesenchymal Stem Cells By Genetic Manipulation

Ohad Karnieli 1, Yael Izhar-Prato 1, Shlomo Bulvik 2, Shimon Efrat 3*

1 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel, and
2 Laniado Medical Center, Nethanya, Israel
3 Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel, and

* To whom correspondence should be addressed. E-mail: sefrat{at}post.tau.ac.il.


  Abstract

Beta-cell replacement is a promising approach for treatment of type 1 diabetes, however it is limited by shortage of pancreas donors. The pluripotent mesenchymal stem cells (MSC) in adult bone marrow (BM) offer an attractive source of stem cells for generation of surrogate beta cells. BM-MSC can be obtained with relative ease from each patient, allowing potential circumvention of allograft rejection. Here we report a procedure for expansion of BM-MSC in vitro and their differentiation into insulin-producing cells. The pancreatic duodenal factor 1 (Pdx1) gene was expressed in BM-MSC from 14 human donors, and the extent of differentiation of these cells towards the beta-cell phenotype was evaluated. RNA and protein analyses documented the activation of expression of all 4 islet hormones. However, the cells lacked expression of NEUROD1, a key transcription factor in differentiated beta cells. A significant insulin content, as well as glucose-stimulated insulin release, were demonstrated in vitro. Cell transplantation into streptozotocin-diabetic immunodeficient mice resulted in further differentiation, including induction of NEUROD1, and reduction of hyperglycemia. These findings were reproducible in BM-MSC cells from 9/14 donors of both sexes, aged 19-62. These results suggest a therapeutic potential for PDX1-expressing BM-MSC in beta-cell replacement in patients with type 1 diabetes.

Key Words. beta-cell replacement, insulin secretion, PDX1, cell transplantation




This article has been cited by other articles:


Home page
 Stem CellsHome page
B. Davani, L. Ikonomou, B. M. Raaka, E. Geras-Raaka, R. A. Morton, B. Marcus-Samuels, and M. C. Gershengorn
Human Islet-Derived Precursor Cells Are Mesenchymal Stromal Cells That Differentiate and Mature to Hormone-Expressing Cells In Vivo
Stem Cells, December 1, 2007; 25(12): 3215 - 3222.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2007 by AlphaMed Press.